Crystalline hydrochloride salt of darunavir
US-9175005-B2 · Nov 3, 2015 · US
US10214538B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10214538-B2 |
| Application number | US-201615211525-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 15, 2016 |
| Priority date | Jul 24, 2012 |
| Publication date | Feb 26, 2019 |
| Grant date | Feb 26, 2019 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention provides a process for the preparation of darunavir or solvates or a pharmaceutically acceptable salt thereof substantially free of bisfuranyl impurities, particularly darunavir propionate solvate. The present invention also provides a process for preparation amorphous darunavir using the darunavir propionate solvate.
Opening claim text (preview).
We claim: 1. A process for preparation of amorphous darunavir, comprising the steps of: a) providing a first solution comprising an acid and a solvent, at a temperature of about −5° C. to about 10° C., wherein the acid is acetic acid and the solvent is either acetonitrile or water; b) adding an amount of darunavir propionate solvate to the first solution to form a second solution; c) combining the second solution of step b) with a base and water at a temperature of about −10° C. to about 0° C., wherein the base is ammonia to form a third solution; and c) recovering the amorphous darunavir from the third solution of step b), wherein the purity of the amorphous darunavir is equal to or greater than about 99.7% as measured by HPLC. 2. The process of claim 1 , wherein the solvent used in the first solution of step a) is acetonitrile. 3. The process of claim 1 , wherein the first solution of step a) is provided at a temperature of about 5° C. to about 10° C. 4. The process of claim 1 , wherein the third solution formed in step b) is subsequently stirred at a temperature of about −10° C. to about −5° C. 5. The process of claim 1 , further comprising forming a pharmaceutical composition by combining the recovered amorphous darunavir with at least one pharmaceutically acceptable excipient. 6. A process for preparation of amorphous darunavir, comprising the steps of: a) forming a first solution by dissolving a darunavir solvate in an acid and a solvent at a temperature of about −5° C. to about 10° C., wherein the acid is acetic acid and the solvent is either acetonitrile or water; b) combining the first solution with a second solution comprising a base and water at a temperature of about −10° C. to about 0° C. to form a third solution; and c) recovering by filtration the amorphous darunavir from the third solution, wherein the purity of the amorphous darunavir is equal to or greater than about 99.7% as measured by HPLC. 7. The process of claim 6 , further comprising: d) combining the recovered amorphous darunavir with at least one pharmaceutically acceptable excipient for use as a pharmaceutical composition. 8. The process of claim 6 , wherein the purified amorphous darunavir includes less than 0.04% as measured by HPLC of any one of:
for HIV · CPC title
Ortho-condensed systems · CPC title
Crystalline forms, e.g. polymorphs · CPC title
by reaction of ammonia or amines with sulfonic acids, or with esters, anhydrides, or halides thereof · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.